Scientists Find Unexpected Discovery in Pet Poop – and It’s Concerning
Isoxazoline Flea and Tick Medications Detected in Pet Waste
Table of Contents
A recent study reveals that isoxazoline-based flea and tick medications persist in the feces of cats and dogs even after treatment concludes,perhaps posing risks to environmental invertebrates.Researchers found these compounds can remain in pet waste and subsequently impact beneficial insects in the wild.
What are Isoxazolines?
Isoxazolines are a class of insecticides used in veterinary medicine to prevent and treat flea and tick infestations in pets. They work by interfering with the nervous system of the parasites. Common isoxazoline drugs include fluralaner, afoxolaner, sarolaner, and lotilaner, often sold under brand names like Bravecto, NexGard, Simparica, and Credelio.
These medications are typically administered orally or topically,and are considered effective in controlling external parasites. However, the new research highlights potential unintended consequences for the environment.
Environmental impact of Isoxazolines
The study, conducted by researchers at the French National Research Institute for Agriculture, Food and Environment (INRAE), detected isoxazoline residues in the feces of treated dogs and cats for up to 28 days after management. The research, published in Environmental Science & Technology, indicates that these compounds are not fully metabolized by the animals and are excreted in thier waste.
This excreted residue can then contaminate soil and waterways, potentially affecting non-target organisms, especially invertebrates like dung beetles and earthworms, which play a crucial role in ecosystem health.The researchers suggest that these insects are exposed to levels of isoxazolines that could be harmful.
Specifically, the study found that isoxazolines can disrupt the nervous system of dung beetles, impacting their ability to reproduce and navigate.INRAE’s press release details the findings, stating that the concentrations detected in the environment could have “sublethal effects” on these insects.
Regulatory Response and Future Research
As of january 14, 2026, no major regulatory changes have been implemented in response to this research. The U.S. Food and Drug Administration (FDA) continues to monitor reports of adverse events associated with isoxazoline drugs in pets, but its current guidance does not address environmental concerns.
Further research is needed to fully understand the long-term ecological effects of isoxazoline contamination. Scientists are investigating the potential for bioaccumulation in the food chain and the impact on a wider range of invertebrate species. The INRAE team is also exploring potential mitigation strategies, such as improved waste management practices for pet owners.